{"id":"ym177","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by activating the GLP-1 receptor, which helps to regulate blood sugar levels and improve insulin sensitivity.","oneSentence":"YM177 is a glucagon-like peptide-1 (GLP-1) receptor agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:13.841Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04093323","phase":"PHASE2","title":"Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2024-11-13","conditions":"HLA-A2 Positive Cells Present, Refractory Melanoma","enrollment":1},{"nctId":"NCT07174570","phase":"PHASE2","title":"Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer","status":"RECRUITING","sponsor":"Emory University","startDate":"2026-01-02","conditions":"Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8","enrollment":39},{"nctId":"NCT06997068","phase":"PHASE2","title":"Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-07-09","conditions":"Metastatic Oral Cavity Carcinoma, Recurrent Oral Cavity Carcinoma, Stage IVC Lip and Oral Cavity Cancer AJCC v8","enrollment":25},{"nctId":"NCT05756166","phase":"PHASE1, PHASE2","title":"Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2024-02-16","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma","enrollment":5},{"nctId":"NCT04162873","phase":"PHASE2","title":"Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer","status":"TERMINATED","sponsor":"University of Utah","startDate":"2019-11-27","conditions":"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Nasal Cavity and Paranasal Sinus Carcinoma","enrollment":13},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT04081389","phase":"PHASE1","title":"Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-12-06","conditions":"Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8","enrollment":9},{"nctId":"NCT03599453","phase":"EARLY_PHASE1","title":"Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-01-09","conditions":"Triple -Negative Breast Cancer, Estrogen Receptor Negative, HER2/Neu Negative","enrollment":8},{"nctId":"NCT00538031","phase":"PHASE2","title":"Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2003-12-22","conditions":"Fallopian Tube Cancer, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer","enrollment":52},{"nctId":"NCT03403634","phase":"PHASE2","title":"Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2018-04-19","conditions":"Metastatic Carcinoma in the Liver, Recurrent Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7","enrollment":19},{"nctId":"NCT00141154","phase":"PHASE3","title":"Comparison Of Celecoxib 200 Mg Bid, Loxoprofen Sodium 60 Mg Tid And Placebo In Low Back Pain In Japan","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-10","conditions":"Low Back Pain","enrollment":1234},{"nctId":"NCT01062113","phase":"PHASE2","title":"Study To Evaluate Efficacy And Safety Of An Additional Dose Of Celecoxib (YM177) In Patients With Post-Tooth Extraction Pain","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2010-04","conditions":"Pain","enrollment":255},{"nctId":"NCT00976716","phase":"PHASE3","title":"An Open-Label Study Of Celecoxib In Patients With Posttraumatic Pain","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2009-09","conditions":"Pain","enrollment":80},{"nctId":"NCT01729923","phase":"PHASE2","title":"A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"University of Washington","startDate":"2013-03","conditions":"Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IVA Colon Cancer","enrollment":27},{"nctId":"NCT00081263","phase":"PHASE2","title":"Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"2005-06","conditions":"Cervical Carcinoma, Cervical Intraepithelial Neoplasia Grade 2/3, Stage 0 Cervical Cancer","enrollment":130},{"nctId":"NCT00499655","phase":"PHASE2","title":"Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2007-11","conditions":"Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer","enrollment":107},{"nctId":"NCT01118572","phase":"PHASE3","title":"A Study to Verify the Efficacy of YM177 (Celecoxib) in Postoperative Pain Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-02","conditions":"Post Operative Pain","enrollment":616},{"nctId":"NCT01158534","phase":"PHASE2","title":"Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2006-03","conditions":"Renal Cell Cancer, Stage IV Renal Cell Cancer","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Celecoxib","Celecox"],"phase":"phase_3","status":"active","brandName":"YM177","genericName":"YM177","companyName":"Astellas Pharma Inc","companyId":"astellas-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"YM177 is a glucagon-like peptide-1 (GLP-1) receptor agonist. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}